Sugi Predict

Sugi Predict / Compounds / SCHEMBL603555

SCHEMBL603555

SCHEMBL603555

O=C(N[C@@H]1CCCC[C@@H]1C(=O)O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SSTR3 P32745 4/20 0.52
▸ NPC1 O15118 3/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ MMP2 P08253 1/20 0.50
▸ MMP7 P09237 1/20 0.50
▸ MMP9 P14780 1/20 0.50
▸ MMP13 P45452 1/20 0.50
▸ APEX1 P27695 1/20 0.49
▸ HTT P42858 1/20 0.48
▸ CCR1 P32246 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MCOLN2 Q8IZK6 1/20 0.47
▸ MCOLN1 Q9GZU1 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46
▸ CGAS Q8N884 1/20 0.46
▸ F10 P00742 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1727942 1.00 SSTR3 (0.52) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL1756678 1.00 SSTR3 (0.52) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL8803719 1.00 SSTR3 (0.52) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL607580 1.00 SSTR3 (0.52) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL1756674 1.00 SSTR3 (0.52) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL5032040 1.00 SSTR3 (0.52) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL1757228 0.97 MMP2 (0.54) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL16489793 0.97 MMP2 (0.54) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL5392135 0.91 RAB9A (0.62) SSTR3NPC1RAB9AMMP2MMP7
SCHEMBL775118 0.89 SSTR3 (0.61) SSTR3NPC1RAB9AMMP2MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441745-B2 Processes and compounds RADIUS PHARMACEUTICALS, INC. (US) 2025-10-14 — — US claimed
US-20230192685-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-06-22 — — US claimed
EP-4163280-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2023-04-12 — — EP claimed
US-20220162233-A1 PROCESSES AND COMPOUNDS RADIUS HEALTH, INC. 2022-05-26 — — US claimed
EP-3924328-A1 PROCESSES AND COMPOUNDS Radius Pharmaceuticals, Inc. (US) 2021-12-22 — — EP claimed
WO-2020167855-A1 PROCESSES AND COMPOUNDS RADIUS PHARMACEUTICALS, INC. (US) 2020-08-20 — — WO claimed
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 — — US claimed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 — — US claimed
US-7214834-B2 Process for preparing enantiomerically pure 1,1′-spirobiindane-6,6′-diol derivatives EASTMAN KODAK COMPANY (US) 2007-05-08 — — US claimed
EP-1768943-A1 PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES EASTMAN KODAK COMPANY (US) 2007-04-04 — — EP claimed
WO-2006019663-A1 PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES EASTMAN KODAK COMPANY (US) 2006-02-23 — — WO claimed
US-20060020150-A1 Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives EASTMAN KODAK COMPANY 2006-01-26 — — US claimed
EP-0354068-B1 Optically active piperazine derivative NIPPON CHEMIPHAR CO (JP) 1994-06-15 — — EP claimed
JP-63054342-A — — None — — JP disclosed
JP-7070070-A — — None — — JP disclosed
JP-63054341-A — — None — — JP disclosed
US-4736060-A Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine NIPPON RIKAGAKUYAKUHIN CO., LTD. (JP) 1988-04-05 — — US disclosed
JP-S6354342-A OPTICAL RESOLUTION OF (+-)-ALPHA-ETHYLBENZYLAMINE DAICEL CHEM IND LTD 1988-03-08 — — JP disclosed
JP-S6354341-A OPTICAL RESOLUTION PROCESS DAICEL CHEM IND LTD 1988-03-08 — — JP disclosed
JP-S5824545-A OPTICAL RESOLUTION OF (+-)-1-(1-NAPHTHYL)ETHYLAMINE NOHIRA HIROYUKI 1983-02-14 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020150-A1 Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives HSD11B1, PKD1, REN SSTR3 1019/4885NPC1 1034/4885RAB9A 3329/4885
US-12441745-B2 Processes and compounds ESR1, ESR2, CYP19A1 SSTR3 1955/4885NPC1 1349/4885RAB9A 2552/4885
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF ACKR3, KIT, C3AR1 SSTR3 2231/4885NPC1 2016/4885RAB9A 1810/4885
US-20230192685-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND MALT1, CYP51A1, ME1 SSTR3 3436/4885NPC1 721/4885RAB9A 2126/4885
US-20220162233-A1 PROCESSES AND COMPOUNDS ESR1, ESR2, CYP19A1 SSTR3 1955/4885NPC1 1349/4885RAB9A 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.